chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the right arm on 08Apr2021 at 16:00 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. On 14Apr2021 at 15:00, the patient experienced joint pain. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event joint pain was not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis, Throat irritation
Clinical narrative: The following day also had a nose bleed; Scratchy throat; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 09:45 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to nuts, allergy to shrimp and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included mometasone furoate (NASONEX), cetirizine hydrochloride (ZYRTEC), ciclesonide (ALVESCO) and vitamins; all taken on unknown date for unknown indication and unknown if ongoing. The patient previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 01Apr2021 at 09:45 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 22Apr2021 at 10:05, after receiving the second vaccine, the patient started to develop a scratchy throat 20 minutes after the injection that lasted the entirety of the day, and on the following day, 23Apr2021, the patient also had a nose bleed. The patient did not receive any treatment for the events. The events did not result in any of these doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken for the reported events. The clinical outcome of the events scratchy throat and nose bleed was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster, SARS-CoV-2 test
Clinical narrative: Developed Shingles 2 days after first dose.; This is a spontaneous report from a contactable nurse, the patient. A 42-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EJ1685) via an unspecified route of administration in the left arm on 30Dec2020 at 12:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Concomitant medication taken within two weeks of vaccination included loratadine (CLARITIN) taken on unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient developed shingles on 01Jan2021, two days after first dose. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles and included treatment with medications like antiviral, antibiotics, pain reliever. Since the vaccination, the patient had been tested for COVID-19. On 16Mar2021, the patient underwent COVID-19 test via nasal swab and the result was negative. The clinical outcome of the event developed shingles two days after first dose was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Menstruation delayed, Pain in extremity
Clinical narrative: Late period.; Thigh pain; Abdominal pain; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 11:30 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 12:00 the patient experienced the events late period, thigh and abdominal pain. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as the result of adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events late period, thigh and abdominal pain were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitis. Onset 02Apr. More pronounced in right ear but persistent 24/7 in both.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7533), via an unspecified route of administration in the left arm on 31Mar2021 at 10:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously took bacitracin (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. On 02Apr2021 at 08:00, the patient experienced tinnitus that was more pronounced in right ear but persistent 24/7 in both. The patient had no prior history of tinnitus. The event did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus that was more pronounced in right ear but persistent 24/7 in both was not resolved at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 21Apr2021 at 16:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 15:45 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not take any concomitant medications. On 22Apr2021, the patient developed shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measure was taken as a result of the event shingles and included treatment with valacyclovir (VALTREX) on an unknown date. The clinical outcome of the event shingles was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram, Rash
Clinical narrative: Experienced small and dense red rash all over right and left arms 5 days after vaccine; Rash at the bottom of face both right and left; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer (post radiation treatment) and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included gabapentin (MANUFACTURER UNKNOWN), duloxetine (MANUFACTURER UNKNOWN), pentoxifylline (MANUFACTURER UNKNOWN), vitamin d nos (MANUFACTURER UNKNOWN) and tocopherol (VITAMIN E); all from unknown dates and for unknow indications and unknown if ongoing. The patient previously received ampicillin (MANUFACTURER UNKNOWN) and experienced allergy. On 19Apr2021, the patient experienced rash at the bottom of the face both right and left. On 20Apr2021, five days after vaccine, the patient experienced small and dense red rash all over right and left arms. It was reported that both rashes were persistent. The patient had no changes in anything for what she was taking orally and had no other injections except a computerized tomography (CT) scan with iodine injection and not allergic to Iodine. The patient wanted to know that whether she should take the second vaccine on 06May2021 or not. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events small and dense red rash all over right and left arms and rash at the bottom of the face both right and left were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Dysphonia, Ear discomfort, Ill-defined disorder, Pain in jaw, Palpitations
Clinical narrative: Heaviness in left jaw, then heaviness in upper right jaw; rush from head to toe; Racing heart; Slight throat swelling; voice sounded funny; Clogged ears; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 28Mar2021 at 12:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included syndrome lupus, antiphospholipid antibodies and raynauds. The patient did not have allergies to medications, food, or other products. Concomitant medications included duloxetine hydrochloride (CYMBALTA), hydroxychloroquine phosphate (PLAQUENIL) and thiamazole (METHIMAZOLE); all taken for an unknown indication on an unspecified date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER6199) via an unspecified route of administration in the left arm on 06Mar2021 at 12:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 13:00, the patient experienced heaviness in left jaw, then heaviness in upper right jaw, then rush from head to toe and racing heart, then slight throat swelling (voice sounded funny) and clogged ears. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events heaviness in left jaw then heaviness in upper right jaw, rush from head to toe, racing heart, slight throat swelling, voice sounded funny and clogged ears were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pharyngeal swelling
Clinical narrative: Heaviness in left jaw, then heaviness in upper right jaw; rush from head to toe; Racing heart; Slight throat swelling; voice sounded funny; Clogged ears; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 28Mar2021 at 12:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included syndrome lupus, antiphospholipid antibodies and raynauds. The patient did not have allergies to medications, food, or other products. Concomitant medications included duloxetine hydrochloride (CYMBALTA), hydroxychloroquine phosphate (PLAQUENIL) and thiamazole (METHIMAZOLE); all taken for an unknown indication on an unspecified date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER6199) via an unspecified route of administration in the left arm on 06Mar2021 at 12:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 13:00, the patient experienced heaviness in left jaw, then heaviness in upper right jaw, then rush from head to toe and racing heart, then slight throat swelling (voice sounded funny) and clogged ears. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events heaviness in left jaw then heaviness in upper right jaw, rush from head to toe, racing heart, slight throat swelling, voice sounded funny and clogged ears were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia, Urticaria
Clinical narrative: Fever 99.7 second day only; starting second day hives, 4th day hives appearing all over body.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 20Apr2021 at 08:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient previously took penicillin for unknown indication and experienced penicillin allergy. Concomitant medications taken within two weeks of vaccination included melatonin (MANUFACTURER UNKNOWN) and diphenhydramine hydrochloride (BENADRYL); both from unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 08:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 12:00, the patient experienced fever 99.7 (units unspecified) on second day only. Starting second day on 21Apr2021 at 12:00, the patient also got hives, fourth day she experienced hives appearing all over body. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever 99.7 (units unspecified) second day only was resolved on 21Apr2021, while that of starting second day hives, fourth day hives appearing all over body was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Malaise, Pain, Pyrexia
Clinical narrative: Chills; Aches; Ran a fever from 99 -101 degree; Still achy/not feeling well; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on 20Apr2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included cerebral palsy and some other mental health diagnoses. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN), ethinylestradiol/ levonorgestrel (SEASONALE) and docusate sodium (COLACE); all for unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 30Mar2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 04:00, 12 hours after the vaccine, the patient woke up with chills and aches. Ran a fever from 99-101 degree until 19:00 with chills and aches. The patient still felt achy/not felt well through next day. The patient also stayed home from school for two days. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 23Apr2021, the patient underwent rapid test via nasal swab and the result was negative. Therapeutic measures were taken as a result of the events and included treatment with one extra strength paracetamol (TYLENOL) every few hours. The clinical outcome of the events ran a fever from 99-101 degree was resolved on 21Apr2021 at 19:00; while that of chills, aches and still achy/not feeling well was resolved in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Chills; Aches; Ran a fever from 99 -101 degree; Still achy/not feeling well; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on 20Apr2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included cerebral palsy and some other mental health diagnoses. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN), ethinylestradiol/ levonorgestrel (SEASONALE) and docusate sodium (COLACE); all for unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 30Mar2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 04:00, 12 hours after the vaccine, the patient woke up with chills and aches. Ran a fever from 99-101 degree until 19:00 with chills and aches. The patient still felt achy/not felt well through next day. The patient also stayed home from school for two days. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 23Apr2021, the patient underwent rapid test via nasal swab and the result was negative. Therapeutic measures were taken as a result of the events and included treatment with one extra strength paracetamol (TYLENOL) every few hours. The clinical outcome of the events ran a fever from 99-101 degree was resolved on 21Apr2021 at 19:00; while that of chills, aches and still achy/not feeling well was resolved in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: After 10 days of my first pfizer covid-19 vaccine shot, I have rash on my face and started to spread to my eye, neck, finger, and hands; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration in the left arm on 02Apr2021 at 11:15 (at the age of 42-year-old) as a single dose for COVID-19 immunization. The patient had no medical history.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 12Apr2021 at 16:00, after ten days of the first vaccine shot, the patient experienced rash on face which started to spread to eye, neck, finger and hands. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events rash on face which started to spread to eye, neck, finger and hands was not recovered at the time of this reported.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles across ribs under my left shoulder blade; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on an unknown date in Apr2021 at 12:15 (at the age of 43-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Apr2021, the patient experienced shingles across ribs under left shoulder blade. Since the vaccination, the patient had not been tested for COVID-19. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of event shingles across ribs under left shoulder blade and included treatment with antiviral medication (unspecified). The clinical outcome of the event shingles across ribs under left shoulder blade was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Pain, Pyrexia
Clinical narrative: Shivers; Headache; Body aches; Fever 102; This is a spontaneous report from a non-contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ep6955) via an unspecified route of administration in the right arm on 20Apr2021 at 04:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination included ascorbic acid (VITAMIN C), cyanocobalamin (VITAMIN B-12) and multi vitamin (reported as multi vit); all from unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ep6955) via an unspecified route of administration in the left arm on 30Mar2021 at 01:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 at 21:45, the patient experienced shivers, headache, body aches, 102 (unspecified units) fever. Therapeutic measures were taken as a result of shivers, headache, body aches, 102 (unspecified units) fever and included treatment with Motrin, following which the patient had a bad reaction and then took Tylenol next day fever decreased. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events shivers, headache, body aches, 102 (unspecified units) fever was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain, Pyrexia
Clinical narrative: Fever; Tired; Aches; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 22Apr2021 at 11:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included iron (MANUFACTURER UNKNOWN) and cyanocobalamin (VITAMIN B-12); both taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 22Apr2021 at 21:00, the patient experienced aches 12 hours later and then headache. On 23Apr2021 after 24 hours, the patient experienced fever and tired as well. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events aches, headache, fever and tired were not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Pain in extremity, SARS-CoV-2 test
Clinical narrative: Left arm is feeling stiff and painful when not moving.; Left arm is feeling stiff and painful when not moving.; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 23Apr2021 at 15:15 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 23Apr2021 at 17:00, The patient experienced her left arm was feeling stiff and painful when not moving. On 18Apr2021, the patient underwent lab tests and procedures, which included COVID 19 nasal swab and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of event left arm feeling stiff and painful when not moving was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Eye contusion
Clinical narrative: Two black eyes within 2 hours of shot; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 14:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included hypercholesterolemia, hay fever and anxiety/depression. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram oxalate (LEXAPRO) and ezetimibe, simvastatin (VYTORIN); both from unknown dates for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 16:30, within 2 hours of shot, the patient experienced two black eyes for which the patient did not take any NSAIDs. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event two black eyes was recovered on an unknown date in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Cough, Pain, Productive cough, Pyrexia
Clinical narrative: Body Aches; Fever (101); Rash (small red spots) on chest and back; Dry/wet cough; Dry/wet cough; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0158) via an unspecified route of administration in the left arm on 21Apr2021 at 12:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included loratadine (CLARITIN), fluticasone propionate (FLONASE), vitamin d nos (MANUFACTURER UNKNOWN) and unspecified multivitamin (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 11:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient previously received fluconazole (MANUFACTURER UNKNOWN) and experienced drug allergy. On 22Apr2021 at 03:00, the patient experienced body aches, fever of 101 (unspecified unit), rash (small red spots) on chest and back and dry/wet cough. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as result of the event fever which included treatment with some paracetamol (TYLENOL). The clinical outcome of the events body aches, fever (101), rash (small red spots) on chest and back and dry/wet cough was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Rash macular
Clinical narrative: Body Aches; Fever (101); Rash (small red spots) on chest and back; Dry/wet cough; Dry/wet cough; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0158) via an unspecified route of administration in the left arm on 21Apr2021 at 12:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included loratadine (CLARITIN), fluticasone propionate (FLONASE), vitamin d nos (MANUFACTURER UNKNOWN) and unspecified multivitamin (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 11:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient previously received fluconazole (MANUFACTURER UNKNOWN) and experienced drug allergy. On 22Apr2021 at 03:00, the patient experienced body aches, fever of 101 (unspecified unit), rash (small red spots) on chest and back and dry/wet cough. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as result of the event fever which included treatment with some paracetamol (TYLENOL). The clinical outcome of the events body aches, fever (101), rash (small red spots) on chest and back and dry/wet cough was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, SARS-CoV-2 test
Clinical narrative: Headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 28Mar2021 at 16:00 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. The medical history of the patient included fruit allergy (melon) and vegetable allergy (carrot). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 07Mar2021 at 14:30 as a single dose for COVID-19 immunisation. On 29Mar2021 at 08:00 the patient experienced headache and fatigues that increased through the day for the last 4 weeks since vaccination, beginning the day after his second shot. Blood work and urinalysis was looked normal, doctor believes that to be vaccine related. Since the vaccination, the patient had been tested for COVID-19.  On 05Apr2021, the patient underwent Nasal Swab and the result was Negative. On an unknown date, the patient underwent Blood test and the result was Normal. On an unknown date, the patient underwent Urine analysis and the result was Normal. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events headache and fatigues that increased through the day was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lymphadenopathy, Musculoskeletal stiffness
Clinical narrative: Swollen lymph node under arm; Stiffness in neck and shoulder on same side of injectionarm.; Headache; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm on 21Apr2021 at 14:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication was not reported. The patient had no known allergies to medications, food and other products. On 23Apr2021 at 08:00, the patient experienced swollen lymph node under arm which was same arm that the shot was administered, headache and stiffness in neck and shoulder on same side of injection arm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen lymph node under arm which was same arm that the shot was administered, headache and stiffness in neck and shoulder on same side of injection arm was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoacusis, Tinnitus
Clinical narrative: Ringing in ears tennitus; muffled hearing in left ear; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 (at the age of 70-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, cholesterol and acid reflux (oesophageal). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amlodipine besylate (MANUFACTURER UNKNOWN) 5mg, unspecified BP med and atorvastatin (MANUFACTURER UNKNOWN) all from an unknown date and unknown if ongoing for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 23Feb2021 at 13:30 (at the age of 70-year-old) as a single dose for COVID-19 immunisation. On 01Apr2021 at 13:45, the patient experienced ringing in ears tennitus and muffled hearing in left ear after the second dose vaccination. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events included treatment with prednisone. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events ringing in ears tennitus and muffled hearing in left ear was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Abnormal dreams, Sleep-related eating disorder, Somnambulism
Clinical narrative: Having concurrent vivid dreams; instances of sleep walking; Sleep eating; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 20Mar2021 at 09:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, allergy to sulfa, pollens, insects, some foods and drug allergy to fluoroquinolones. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC), vitamin d nos (MANUFACTURER UNKNOWN)), sambucus nigra (ELDERBERRY), zinc (MANUFACTURER UNKNOWN) and slow release (MANUFACTURER UNKNOWN), all for unknown indications from an unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknwon) via an unspecified route of administration in the left arm on 27Feb2021 at 09:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 09Apr2021 at 22:30, the patient experienced concurrent vivid dreams, instances of sleepwalking and sleep eating. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events concurrent vivid dreams, instances of sleepwalking and sleep eating was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Lymph node pain, Lymphadenopathy, Pyrexia
Clinical narrative: painful lymph node under arm; Swollen lymph node under arm where vaccine was administered; Temperature under that arm was101.4 while under the other arm was99; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 22Apr2021 at 16:00 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. Medical history included high liver enzymes and high cholesterol. The patient had no known allergies. Concomitant medications included fish oil (MANUFACTURER UNKNOWN) and silybum marianum (MILK THISTLE) both for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 31Mar2021 at 16:00 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 10:00, the patient experienced swollen and painful lymph node under arm where vaccine was administered and temperature under that arm was 101.4 (units unspecified) while under the other arm was 99 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph node, painful lymph node and temperature under that arm was 101.4 (units unspecified) while under the other arm was 99 (units unspecified) was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph node in left armpit; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 13Apr2021 at 12:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included nickel sensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications and did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 18:00, the patient experienced swollen lymph node in left armpit. The event did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The patient did not receive any treatment for swollen lymph node in left armpit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph node in left armpit was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.